

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 15**

---

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION  
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934  
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934.**

001-39743  
Commission File Number

---

**KINNATE BIOPHARMA INC.**

(Exact name of registrant as specified in its charter)

---

2200 Powell Street, Suite 310  
Emeryville, California 94608  
(510) 204-7200

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Common Stock, \$0.0001 par value per share  
(Title of each class of securities covered by this Form)

None  
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

---

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	<input checked="" type="checkbox"/>
Rule 12g-4(a)(2)	<input type="checkbox"/>
Rule 12h-3(b)(1)(i)	<input checked="" type="checkbox"/>
Rule 12h-3(b)(1)(ii)	<input type="checkbox"/>
Rule 15d-6	<input type="checkbox"/>
Rule 15d-22(b)	<input type="checkbox"/>

Approximate number of holders of record as of the certification or notice date: One

Pursuant to the requirements of the Securities Exchange Act of 1934, Kinnate Biopharma Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: April 17, 2024

**KINNATE BIOPHARMA INC.**

By: /s/ Owen Hughes

Name: Owen Hughes

Title: *President, Treasurer and Secretary*

---

---